Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster

Silva Jr, Almir Ribeiro da; Villas-Boas, Lucy Santos; Paula, Anderson Vicente de; Tozetto-Mendoza, Tania Regina; Honorato, Layla; Witkin, Steven S.; Mendes-Correa, Maria Cassia.
Rev. Inst. Med. Trop. São Paulo (Online) ; 64: e43, 2022. tab
Artigo em Inglês | LILACS-Express | ID: biblio-1387340

Documentos relacionados

  1. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
  2. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.
  3. Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals.
  4. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination.
  5. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses.
  6. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase.
  7. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infection.
  8. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses.
  9. Memory CD8<sup>+</sup> T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination.
  10. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.